EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults

Fumio Otsuka, Keiko Hanabara, Seigo Akari, Katsunori Kitamoto, Yosuke Inagaki, Dylan Glatt, Harumi Murakami, Naoki Uchida

Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)

DOI: 10.1002/cpdd.70085 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 24.07.2026. Verfasst von Fumio Otsuka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Receptors, Somatostatin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paltusotine is a novel, nonpeptide, once‐daily oral, selective somatostatin 2 receptor (SST2) agonist. We evaluated the pharmacokinetics, pharmacodynamics, and safety of oral paltusotine in healthy Japanese adults in single‑dose (20, 40, 60, 80 mg) and repeated‑dose (40 mg once daily for 7 days in a two‐sequence, two‑period crossover design) studies. In addition, the effects of food intake and pharmacodynamics were examined in the repeated‐dose study. Eight participants were enrolled in each dose of the single‐dose study, and 12 participants were enrolled in the repeated‐dose study. In both studies, there were no deaths, serious adverse events, or severe adverse events. In the single‐dose study, plasma paltusotine exposures increased in a dose‐dependent manner for the dose range of 20 to 80 mg (based on C max and AUC 0‐∞ ), and the elimination half‐life (t 1/2 ) was 24‐28 h. In the repeated‐dose study, similar reductions from baseline in serum insulin‐like growth factor‐1 (IGF‐I) were observed for 1‐h pre‐prandial (−60.1 ± 26.0 ng/mL) and 3‐h post‐prandial administration (−61.6 ± 17.7 ng/mL) on Day 7. Overall, this study establishes the pharmacokinetics, pharmacodynamics, and safety in healthy Japanese adults to support the development of paltusotine as a treatment for acromegaly and pituitary gigantism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, SomatostatinAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveCross-Over StudiesDose-Response Relationship, DrugDrug Administration ScheduleHalf-LifeHealthy VolunteersInsulin-Like Growth Factor IJapanEast Asian PeopleNitrilesPiperidines

Stichwörter der Autor:innen

IGF‐ISST2acromegalyhealthy Japanese adultspaltusotine (CRN00808/SK‐5307)

Substanzen

Insulin-Like Growth Factor IPaltusotineReceptors, Somatostatinsomatostatin receptor 2NitrilesPiperidines

Autor:innen und Institutionen

  • Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Medical Affairs Group, Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
  • Project Management Group, Project Management Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
  • Clinical Development Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
  • Crinetics Pharmaceuticals, Inc., San Diego, USA.
  • Souseikai Sumida Hospital, Tokyo, Japan.

Zitieren

APA

Otsuka, F., Hanabara, K., Akari, S., Kitamoto, K., Inagaki, Y., Glatt, D., Murakami, H., & Uchida, N. (2026). Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70085

Vancouver

Otsuka F, Hanabara K, Akari S, Kitamoto K, Inagaki Y, Glatt D, et al. Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70085

BibTeX
@article{Otsuka2026,
  author = {Otsuka, Fumio and Hanabara, Keiko and Akari, Seigo and Kitamoto, Katsunori and Inagaki, Yosuke and Glatt, Dylan and Murakami, Harumi and Uchida, Naoki},
  title = {Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cpdd.70085}
}
Kostenlos starten →